Vizsgálati helyszín
Oncology Hematology Associates
Springfield, Missouri 65807, Egyesült ÁllamokMég nincs intézményhez kötve
- 17futó vizsgálat
- 5lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 22 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis12 vizsgálat
- 2. fázis6 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Toboroz12 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Lezárult4 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Tempus AI4 vizsgálat
- Amgen3 vizsgálat
- Eli Lilly and Company3 vizsgálat
- Janssen Research & Development, LLC3 vizsgálat
- BeOne Medicines2 vizsgálat
- és még 7
Futó vizsgálatok
Toboroz
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· 3. fázis· Eli Lilly and Company· Forrás
Contact: Viran Holden (principal investigator)
Toboroz
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· 3. fázis· Eli Lilly and Company· Forrás
Contact: Viran Holden (principal investigator)
Toboroz
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301· 3. fázis· Takeda· Forrás
Contact: Roger Holden (principal investigator)
Toboroz
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT07211178· Tempus AI· Forrás
Contact: Adrianna Moore
Toboroz
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
NCT06745908· 3. fázis· ImmunityBio, Inc.· Forrás
Contact: Adrianna Moore, RN
Toboroz
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671· 3. fázis· BeOne Medicines· Forrás
Contact: Study Director
Toboroz
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285· 2. fázis· Puma Biotechnology, Inc.· Forrás
Contact: Puma Biotechnology, Inc. Clinical Operations Senior Director
Toboroz
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
NCT06163534· Tempus AI· Forrás
Contact: Adrianna Moore
Toboroz
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273· 2. fázis· Allogene Therapeutics· Forrás
Contact: Robert Ellis, MD (principal investigator)
Fut, nem toboroz
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036· 3. fázis· Amgen· Forrás
Fut, nem toboroz
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· 3. fázis· Eli Lilly and Company· Forrás
Contact: Viran Holden (principal investigator)
Fut, nem toboroz
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555· 3. fázis· Amgen· Forrás
Toboroz
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114· Tempus AI· Forrás
Contact: Adrianna Moore
Fut, nem toboroz
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· 3. fázis· BeOne Medicines· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek